CFB
SPRO icon

Cullen/Frost Bankers’s Spero Therapeutics SPRO Stock Holding History

Cullen/Frost Bankers’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,000
Closed -$6.99K – 1537
2025
Q4 		$6.99K Buy
+3,000
New +$6.97K ﹤0.01% 1156
2025
Q3 		– Sell
-2,000
Closed -$5.8K – 1436
2025
Q2 		$5.8K Hold
2,000
– – ﹤0.01% 1085
2025
Q1 		$1.44K Hold
2,000
– – ﹤0.01% 1189
2024
Q4 		$2.06K Hold
2,000
– – ﹤0.01% 1146
2024
Q3 		$2.68K Hold
2,000
– – ﹤0.01% 1090
2024
Q2 		$2.6K Buy
+2,000
New +$3.02K ﹤0.01% 1072
2023
Q4 		– Sell
-2,000
Closed -$2.42K – 1169
2023
Q3 		$2.42K Hold
2,000
– – ﹤0.01% 1048
2023
Q2 		$2.9K Hold
2,000
– – ﹤0.01% 1023
2023
Q1 		$2.9K Hold
2,000
– – ﹤0.01% 1074
2022
Q4 		$3.46K Hold
2,000
– – ﹤0.01% 992
2022
Q3 		$4K Hold
2,000
– – ﹤0.01% 1024
2022
Q2 		$1K Buy
2,000
+1,000
+100% +$2.91K ﹤0.01% 1043
2022
Q1 		$9K Hold
1,000
– – ﹤0.01% 953
2021
Q4 		$16K Hold
1,000
– – ﹤0.01% 919
2021
Q3 		$18K Hold
1,000
– – ﹤0.01% 1004
2021
Q2 		$14K Hold
1,000
– – ﹤0.01% 1033
2021
Q1 		$15K Hold
1,000
– – ﹤0.01% 881
2020
Q4 		$19K Buy
+1,000
New +$15.6K ﹤0.01% 851

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cullen/Frost Bankers's SPRO Position: Q1 2026 in Review

Cullen/Frost Bankers sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 3,000 shares — an estimated $6.99K sold.

Cullen/Frost Bankers first reported a position in SPRO in Q4 2020 and held it in 18 quarters. The position peaked at $19K in Q4 2020. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Cullen/Frost Bankers reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cullen/Frost Bankers sold 3,000 Spero Therapeutics shares in Q1 2026, an estimated $6.99K.
  • Cullen/Frost Bankers first reported a position in Spero Therapeutics in Q4 2020 and held it in 18 quarters.
  • Cullen/Frost Bankers's Spero Therapeutics position peaked at $19K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.